Literature DB >> 25898834

Immunotherapy Slows TNBC Progression.

.   

Abstract

The experimental monoclonal antibody MPDL3280A extended progression-free survival and produced durable responses in some patients with triple-negative breast cancer, according to preliminary results from a phase I trial. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25898834     DOI： 10.1158/2159-8290.CD-NB2015-059

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  3 in total

1.  A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer.

Authors:  Toshiaki Iwase; Kim R M Blenman; Xiaotong Li; Emily Reisenbichler; Robert Seitz; David Hout; Tyler J Nielsen; Brock L Schweitzer; Daniel B Bailey; Yichao Shen; Xiang Zhang; Lajos Pusztai; Naoto T Ueno
Journal:  Cancers (Basel)       Date:  2021-09-28       Impact factor: 6.639

2.  Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

Authors:  Brian D Lehmann; Bojana Jovanović; Xi Chen; Monica V Estrada; Kimberly N Johnson; Yu Shyr; Harold L Moses; Melinda E Sanders; Jennifer A Pietenpol
Journal:  PLoS One       Date:  2016-06-16       Impact factor: 3.240

Review 3.  Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.

Authors:  Nan Wu; Jinghua Zhang; Jing Zhao; Kun Mu; Jun Zhang; Zhao Jin; Jinpu Yu; Juntian Liu
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.